Trial Profile
A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF-α therapy
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 29 Dec 2021
Price :
$35
*
At a glance
- Drugs Ocrelizumab (Primary) ; Disease-modifying antirheumatics; Leflunomide; Methotrexate; Methotrexate
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms SCRIPT
- Sponsors Genentech
- 24 Dec 2021 This trial was completed in Belgium, according to European Clinical Trials Database.
- 08 Aug 2019 Status changed to discontinued.
- 12 Nov 2018 Status changed from active, no longer recruiting to completed.